paclitaxel has been researched along with Lung Adenocarcinoma in 83 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 50 (60.24) | 24.3611 |
| 2020's | 33 (39.76) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, YW; Choi, HW; Choi, IS; Choi, JH; Lee, HW; Lee, JY; Lee, KT; Park, JY; Rim, HK | 1 |
| Fang, J; Ge, C; Jin, N; Li, X; Li, Y; Liu, Z; Shang, C; Song, G; Sun, L; Xiu, Z; Yang, X; Zhu, Y | 1 |
| Hong, SY; Hsiao, SH; Kao, YR; Lee, MH; Lin, YP; Lu, YC; Wang, CY; Wu, CW | 1 |
| Hu, QH; Huang, SH; Lin, J; Wang, QY; Zhou, QH | 1 |
| Cao, F; Cao, Y; Chen, J; Wei, S; Xing, W; Zhu, X | 1 |
| Feng, J; Han, Y; Hu, G; Hu, M; Li, Z; Ren, J; Zhang, M; Zhang, Y | 1 |
| Chen, H; Fang, S; Hu, Z; Li, N; Liu, K; Pan, Q; Wei, Y; Xu, G; Xu, S; Zhu, L; Zhu, Y | 1 |
| Gao, S; Liu, J; Wen, M; Yang, X; Yu, Q | 1 |
| Hu, W; Li, C; Ma, Y; Wang, M; Wang, S; Wang, W; Wu, B; Zhang, D | 1 |
| Bradford, DS; Crane, J; Deal, AM; Irvin, W; Lee, C; Morgensztern, D; Muss, HB; Pecot, C; Pennell, N; Socinski, M; Stevenson, JP; Stinchcombe, T; Villaruz, LC; Weiss, JM; West, HJ | 1 |
| Gundu, N; Jain, D; Kancharla, H; Khurana, S; Kumar, S; Malik, PS; Mohan, A; Pathak, N; Pathy, S; Pushpam, D; Vandidassane, I | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Gao, J; Pu, J; Shen, J; Yanling, M; Zhong, Z | 1 |
| Ni, J; Zhang, L; Zhang, X | 1 |
| Barberi-Heyob, M; Frochot, C; Jouan-Hureaux, V; Lirdprapamongkol, K; Niamsiri, N; Pramual, S; Svasti, J | 1 |
| Chen, H; Li, J; Liang, X; Pu, X; Shen, T; Song, Z; Wang, L; Wang, W; Xu, C; Yu, Z; Zhang, Y | 1 |
| An, T; Chen, H; Chi, Y; Duan, J; Liang, Q; Wang, J; Wang, S; Wang, Y; Wang, Z; Yang, X; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Li, J; Li, W; Liang, L; Liu, Z; Wang, Y; Xu, F; Xu, H; Yang, G; Yang, L; Ying, J; Zhang, Q; Zhang, S | 1 |
| Jiang, W; Lizaso, A; Mao, X; Mi, J; Song, L; Yang, N; Zeng, L; Zhang, Y; Zhou, Y | 1 |
| Gao, Y; Hou, D; Huang, Z | 1 |
| Andrade, CF; Figueiró, F; Filippi-Chiela, E; Gonzalez, EA; Klamt, F; Nunes, V; Pilar, ES; Solari, JIG | 1 |
| Brat, K; Jakubíková, L; Šťastná, N | 1 |
| Ambrogio, C; Barbacid, M; Cabrera, N; Darbo, E; Drogat, B; Falcone, M; Herfs, M; Jänne, PA; Lacouture, A; Maraver, A; Mosteiro, M; Nadal, E; Nokin, MJ; Prouzet-Mauleon, V; Pujol, JL; San José, S; Santamaría, D; Travert, C; Turcq, B; Villanueva, A; Wang, H | 1 |
| Li, X; Wang, L; Yu, J | 1 |
| Al-Nsour, MA; Carbone, DP; Dakhil, CSR; Das, MS; de Aquino, MTP; Gerber, DE; Horn, L; Johnson, ML; Lee, JW; Liu, JJ; Patel, JD; Ramalingam, S; Schiller, JH; Shanker, A; Wagner, H | 1 |
| Liu, L; Lizaso, A; Xu, Q; Zhang, Y | 1 |
| Aoki, M; Hasegawa, Y; Hatayama, Y; Ishioka, Y; Itoga, M; Makiguchi, T; Okumura, F; Shiratori, T; Tabe, C; Taima, K; Tanaka, H; Tasaka, S; Yokouchi, J | 1 |
| Hu, X; Wang, Z; Yuan, S; Zhao, Y | 1 |
| Ahamad, N; Banerjee, R; Bhatia, E; Joshi, N; Kaviratna, A; Shanmugam, T | 1 |
| Gurvitch, R; Sethwala, A; Wang, B | 1 |
| Egawa, T; Maeda, I; Masuzawa, K; Nakayama, S; Suzuki, Y; Tsunematsu, S | 1 |
| Hu, X; Wu, H; Xu, L | 1 |
| Egger, EK; Lau, JF; Lindner, K; Marinova, M; Mustea, A; Ralser, DJ; Recker, F; Savchenko, O | 1 |
| Dalin, S; Fowler, CE; Garg, S; Hemann, MT; Lees, JA; Moiso, E; Mueller, HS; Udomlumleart, T | 1 |
| Imamura, F; Inoue, T; Kimura, M; Kumagai, T; Nishino, K; Tamiya, M | 1 |
| Gu, FF; Hong, XH; Liang, JY; Liu, L; Liu, YY; Tong, F; Zeng, YL; Zhang, K | 1 |
| Huang, J; Ren, K; Shi, W; Xu, R; Zhao, J | 1 |
| Belka, C; Lauber, K; Orth, M; Schoetz, U; Unger, K | 1 |
| Argiris, A; Choong, NW; Evans, TL; Hansen, RM; Hugec, V; Lee, JW; Ramalingam, SS; Saltzman, JN; Schiller, JH; Song, W; Stevenson, J; Sulecki, MG | 1 |
| Bertino, JR; Fischer, BS; Khiabanian, H; Lee, FY; Morgan, KM; Pine, SR; Rosenfeld, J; Shah, JJ; Singh, A | 1 |
| Chen, FF; Lin, XY; Song, YH; Zhang, CQ | 1 |
| Agócs, L; Döme, B; Fábián, K; Fillinger, J; Kajdácsi, Z; Moldvay, J; Pipek, O; Reiniger, L; Rojkó, L; Szállási, Z; Téglási, V; Tímár, J; Vágvölgyi, A | 1 |
| Huang, QQ; Li, Y; Song, WW; Wang, Y; Wu, JQ; Xu, W; Yin, Y; Yuan, WW; Zhao, WH | 1 |
| Hata, N; Kuronuma, K; Tsujita, T | 1 |
| Cao, S; Han, B; Teng, J; Xu, J; Zhong, H | 1 |
| Li, CX; Xie, T; Zeng, YJ; Zeng, YY; Zeng, ZW; Zhang, NN | 1 |
| Cheng, Y; Kang, JH; Kim, JO; Oh, JE; Shin, JY; Zhang, XH | 1 |
| Liu, L; Song, Y; Zhan, Q; Zhao, Z; Zhou, W | 1 |
| Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
| Cao, B; Liang, L; Xiao, Y | 1 |
| He, J; Hoffman, RM; Li, H; Zhong, N | 1 |
| Chen, CY; Chiou, JF; Ho, CT; Lai, KG; Lin, YH; Liu, TZ; Peng, CY | 1 |
| Choe, KH; Choi, SY; Han, HS; Hong, JM; Hong, KP; Ji, GY; Ji, HJ; Kim, SR; Kim, SW; Kim, YB; Koo, JH; Lee, GK; Lee, HC; Lee, KH; Lee, KM; Lee, OJ; Lee, YM; Moon, YR; Shin, MH; Song, HG; Yi, JH; Yoon, S | 1 |
| Aggarwal, C; Bauml, J; Brady, AK; Cohen, RB; Evans, TL; Judy, B; Langer, C; McNeill, JD; Vachani, A | 1 |
| Bosenberg, MW; Held, MA; Iyidogan, P; Langdon, CG; Levy, F; Mamillapalli, R; Platt, JT; Stern, DF; Theodosakis, N; Vuagniaux, G; Wang, S; Wiedemann, N | 1 |
| Dong, XP; Jiang, N; Jiang, XT; You, QY; Zhang, SL; Zhao, XG | 1 |
| Ambrogio, C; Barbacid, M; Blasco, RB; Crosetto, N; Ding, K; Falcone, M; Fernández-Marcos, PJ; Gómez-López, G; Hidalgo, M; Nadal, E; Ren, X; Sánchez-Céspedes, M; Santamaría, D; Serrano, M; Vidal, A; Villanueva, A; Wang, Z | 1 |
| Azghari, I; Boukir, A; Boutayeb, S; El Ghissassi, I; El Kabous, M; Errrihani, H; Mrabti, H | 1 |
| Dai, Z; Diao, Y; Kang, H; Lin, S; Ma, X; Min, W; Wang, X; Zhao, Y | 1 |
| Fujino, T; Niwa, H; Shitara, M; Suzuki, E; Tanahashi, M; Yoshii, N; Yukiue, H | 1 |
| Endo, H; Katayama, K; Takahashi, Y; Tanaka, T | 1 |
| Boudjemaa, A; Caliez, J; Chouaid, C; Jabot, L; Leroy, K; Monnet, I; Pujals, A; Rousseau-Bussac, G | 1 |
| Chen, DT; Chen, L; Chiappori, AA; Creelan, BC; Cress, WD; Engel, BE; Eschrich, SA; Gray, JE; Haura, EB; Kurtyka, CA; Muñoz-Antonia, T; Ramirez, JL; Rivera, JI; Rosell, R; Schabath, MB; Welsh, EA; Yoder, SJ | 1 |
| Chakrabarti, G; Choudhury, D; Das Mukherjee, D; Das, A; Das, N; Datta, S; Roy, SS | 1 |
| Bao, GL; Lu, J; Sha, HF; Sun, QL; Xie, YY; Yang, XH | 1 |
| Chen, R; Chen, TS; Guo, WJ; Wang, XP | 1 |
| Chang, JY; Chang, WT; Huang, WL; Lai, WW; Lin, CC; Su, WC; Yeh, HH | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Abdel-Nabi, H; Bernacki, R; Cui, H; Mousa, SA; Phillips, PG; Sajjad, M; Veith, J; Yalcin, M | 1 |
| Shepherd, FA | 1 |
| Armour, AA; Chao, TY; Chu, DT; Duffield, EL; Fukuoka, M; Jiang, H; Leong, SS; Mok, TS; Nakagawa, K; Rukazenkov, Y; Saijo, N; Speake, G; Sriuranpong, V; Sunpaweravong, P; Thongprasert, S; To, KF; Wu, YL; Yang, JC | 1 |
| Banerjee, R; Joshi, N; Kaviratna, A; Shanmugam, T | 1 |
| Wang, D; Wang, G; Yang, XQ; Yang, ZZ; Zeng, LL; Zhang, ZM | 1 |
| Fujioka, S; Haruki, T; Miwa, K; Nakamura, H; Takagi, Y; Taniguchi, Y; Yurugi, Y | 1 |
| Gu, H; Liu, Q; Sun, W; Xia, W; Xie, QR; Zhang, J | 1 |
| Antoine, M; Beau-Faller, M; Bergot, E; Brambilla, E; Braun, D; Creveuil, C; de Fraipont, F; Debieuvre, D; Favrot, MC; Hainaut, P; Levallet, G; Milleron, B; Morin, F; Moro-Sibilot, D; Mounawar, M; Quoix, E; Richard, N; Rouquette, I; Westeel, V; Zalcman, G | 1 |
| Juergens, R; Levine, MN | 1 |
| Liu, X; Wang, L; Wu, W; Wu, Y | 1 |
| Chu, DT; Duffield, E; Fukuoka, M; Han, B; Jiang, H; Liao, M; Liu, X; Mok, T; Wu, YL; Zhang, L; Zhou, C | 1 |
| Chen, H; Chen, WJ; Xiong, JP; Yuan, SF; Zheng, WE; Zhu, LJ | 1 |
| Schreiber, J; Waldburg, N | 1 |
| Armstrong, K; Asch, DA; Bristol Demeter, M; Handorf, EA; Langer, CJ; McElligott, S; Vachani, A | 1 |
| Jiang, SJ; Zhang, QC; Zhang, S | 1 |
10 trial(s) available for paclitaxel and Lung Adenocarcinoma
| Article | Year |
|---|---|
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Albumins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Vaccines; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Immunotherapy; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Paclitaxel; Prognosis; Survival Rate | 2020 |
A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2021 |
Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate | 2017 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cell Line, Tumor; Chemotherapy, Adjuvant; E2F Transcription Factors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Time Factors; Transcriptome; Treatment Outcome | 2016 |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Calcium-Calmodulin-Dependent Protein Kinases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoskeleton; Death-Associated Protein Kinases; Deoxycytidine; Disease-Free Survival; DNA Methylation; ErbB Receptors; Female; Gemcitabine; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; China; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Quality of Life; Quinazolines | 2012 |
73 other study(ies) available for paclitaxel and Lung Adenocarcinoma
| Article | Year |
|---|---|
T-type Ca2+ channel blocker, KYS05047 induces G1 phase cell cycle arrest by decreasing intracellular Ca2+ levels in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Quinazolines; Transplantation, Heterologous | 2012 |
Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo.
Topics: Adenocarcinoma of Lung; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Xenograft Model Antitumor Assays | 2022 |
Stabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Aurora Kinase A; Cell Line, Tumor; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-cbl; Ubiquitination | 2022 |
Surface charge switchable nano-micelle for pH/redox-triggered and endosomal escape mediated co-delivery of doxorubicin and paclitaxel in treatment of lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Animals; Doxorubicin; Drug Carriers; Drug Delivery Systems; Endosomes; Hydrogen-Ion Concentration; Mice; Micelles; Neoplasms; Oxidation-Reduction; Paclitaxel; Tumor Microenvironment | 2022 |
Targeted Therapy of Lung Adenocarcinoma by the Nanoplatform Based on Milk Exosomes Loaded with Paclitaxel.
Topics: Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Exosomes; Humans; Lung Neoplasms; Milk; Paclitaxel | 2022 |
Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I-III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity.
Topics: Adenocarcinoma of Lung; Carboplatin; Carrier Proteins; CDC2-CDC28 Kinases; Cell Cycle Proteins; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Prognosis; Tumor Microenvironment | 2022 |
Bioinformatics algorithm for lung adenocarcinoma based on macropinocytosis-related long noncoding RNAs as a reliable indicator for predicting survival outcomes and selecting suitable anti-tumor drugs.
Topics: Adenocarcinoma of Lung; Algorithms; Antineoplastic Agents; Computational Biology; CTLA-4 Antigen; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Prognosis; RNA, Long Noncoding | 2022 |
Topics: Adenocarcinoma of Lung; Cell Proliferation; DEAD-box RNA Helicases; DNA Damage; DNA Helicases; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Paclitaxel; RNA, Long Noncoding | 2023 |
Effects of TRAF3 on the proliferation and migration of lung adenocarcinoma depend partly on pyroptosis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel; Pyroptosis; Sincalide; TNF Receptor-Associated Factor 3 | 2023 |
Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Adenocarcinoma of Lung; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Movement; Cytoskeletal Proteins; Disease-Free Survival; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel; Tumor Suppressor Proteins | 2020 |
Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Creatine Kinase; Humans; Hypothyroidism; Lung Neoplasms; Male; Middle Aged; Muscular Diseases; Paclitaxel; Thyroxine | 2020 |
Overcoming the diverse mechanisms of multidrug resistance in lung cancer cells by photodynamic therapy using pTHPP-loaded PLGA-lipid hybrid nanoparticles.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Lipids; Lung Neoplasms; Nanoparticles; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Polylactic Acid-Polyglycolic Acid Copolymer; Porphyrins | 2020 |
Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins, Fusion; Paclitaxel; Pemetrexed; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Retrospective Studies; Survival Rate | 2020 |
Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Albumins; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Docetaxel; Female; Gemcitabine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncogene Fusion; Paclitaxel; Pemetrexed; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Retrospective Studies; Treatment Outcome | 2020 |
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Paclitaxel; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2020 |
Interleukin-22 enhances chemoresistance of lung adenocarcinoma cells to paclitaxel.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression; Humans; Interleukin-22; Interleukins; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Smoking | 2020 |
Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Apoptosis; Autophagy; Calreticulin; Carboplatin; Caspase 3; Cell Survival; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; HMGB1 Protein; Humans; Immunogenic Cell Death; Lung Neoplasms; Paclitaxel; Prognosis | 2020 |
Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Bevacizumab; Carboplatin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Salvage Therapy | 2020 |
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Discoidin Domain Receptor 1; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mutation; Paclitaxel; Proto-Oncogene Proteins p21(ras); Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Humans; Immune Checkpoint Inhibitors; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation, Missense; Paclitaxel; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2020 |
A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".
Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Humans; Immune Checkpoint Inhibitors; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation, Missense; Paclitaxel; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2020 |
Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.
Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Immunologic Factors; Lenalidomide; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Rituximab | 2020 |
Aerosol Delivery of Paclitaxel-Containing Self-Assembled Nanocochleates for Treating Pulmonary Metastasis: An Approach Supporting Pulmonary Mechanics.
Topics: Adenocarcinoma of Lung; Aerosols; Animals; Humans; Lung; Lung Neoplasms; Mice; Paclitaxel | 2021 |
Type 1 Kounis syndrome after paclitaxel infusion in a patient treated for lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Humans; Kounis Syndrome; Lung Neoplasms; Paclitaxel | 2021 |
Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Paclitaxel | 2021 |
Histone demethylase KDM5A enhances cell proliferation, induces EMT in lung adenocarcinoma cells, and have a strong causal association with paclitaxel resistance.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents, Phytogenic; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; Paclitaxel; Retinoblastoma-Binding Protein 2 | 2021 |
Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; DNA-Binding Proteins; Female; Humans; Immunotherapy; Middle Aged; Mutation; Paclitaxel; Receptor, ErbB-2; Transcription Factors; Vaginal Neoplasms | 2021 |
Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; Mutation; Paclitaxel; Protein-Arginine N-Methyltransferases; Stathmin | 2021 |
Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Drug Combinations; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Nivolumab; Oxonic Acid; Paclitaxel; Tegafur; Tomography, X-Ray Computed | 2017 |
Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel | 2017 |
Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; Potassium Channels, Voltage-Gated; RNA, Long Noncoding | 2017 |
Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aneuploidy; Antineoplastic Agents; Aurora Kinase A; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Chemoradiotherapy; Cohort Studies; Datasets as Topic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mitosis; Nuclear Proteins; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; RNA, Small Interfering; Spindle Apparatus; Survival Analysis; Taxoids; Treatment Outcome | 2018 |
Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Phytogenic; Benzodiazepinones; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Paclitaxel; Transfection | 2017 |
Upregulation of Neural Precursor Cell Expressed Developmentally Downregulated 4-1 is Associated with Poor Prognosis and Chemoresistance in Lung Adenocarcinoma.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Male; Nedd4 Ubiquitin Protein Ligases; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction; Ubiquitin-Protein Ligases; Ubiquitination; Up-Regulation | 2018 |
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Programmed Cell Death 1 Receptor | 2018 |
Membrane-Bound CD40L Promotes Senescence and Initiates Senescence-Associated Secretory Phenotype via NF-κB Activation in Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents, Phytogenic; CD40 Ligand; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Histones; Humans; I-kappa B Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Paclitaxel; RNA Interference; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2018 |
[A Case in Which Good Control of Carcinomatous Serositis Was Achieved Using Chemotherapy Including Albumin-Bound Paclitaxel(Nab-PTX)for Advanced-Stage Pulmonary Adenocarcinoma Exhibiting Carcinomatous Pleurisy and Carcinomatous Pericarditis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pericarditis; Pleurisy; Serositis | 2018 |
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine | 2019 |
The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Liposomes; Mice; Molecular Structure; Paclitaxel; Particle Size; Sesquiterpenes; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Gene Knockdown Techniques; Genes, ras; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; RNA, Small Interfering; Transfection; Tumor Cells, Cultured | 2013 |
[Effects of AS1411 on the apoptosis of taxol-resistant lung adenocarcinoma A549 cell].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Aptamers, Nucleotide; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Humans; Lung Neoplasms; Oligodeoxyribonucleotides; Paclitaxel; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2014 |
[Nimotuzumab significantly enhances chemosensitivity of
PC9 human lung adenocarcinoma cells to paclitaxel in vitro].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Lung Neoplasms; Paclitaxel | 2015 |
Drug exposure in a metastatic human lung adenocarcinoma cell line gives rise to cells with differing adhesion, proliferation, and gene expression: Implications for cancer chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cisplatin; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel | 2015 |
Paclitaxel pretreatment overcomes hypoxia inducible factor-1α-induced radioresistance acquisition of human hepatoma and lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Signal Transduction | 2015 |
Therapeutic effect of anti CEACAM6 monoclonal antibody against lung adenocarcinoma by enhancing anoikis sensitivity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Amino Acid Sequence; Animals; Anoikis; Antibodies, Monoclonal; Antigens, CD; Carcinogenesis; Caspases; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Enzyme Activation; Epitopes; GPI-Linked Proteins; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Molecular Sequence Data; Paclitaxel; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-akt | 2015 |
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Philadelphia; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azepines; Azocines; Benzhydryl Compounds; Camptothecin; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Paclitaxel; Signal Transduction; Taxoids; Time Factors; Topoisomerase Inhibitors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Diterpenes; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epoxy Compounds; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; NF-kappa B; Paclitaxel; Phenanthrenes; S Phase; Signal Transduction; Time Factors | 2016 |
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dasatinib; Discoidin Domain Receptor 1; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Membrane Proteins; Mice; Middle Aged; Mutation; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Proto-Oncogene Proteins p21(ras); Receptor Protein-Tyrosine Kinases; Receptors, Notch; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2016 |
[An intra-thyroid metastasis revealing non-small cell lung cancer].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dysphonia; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Thyroid Neoplasms; Thyroidectomy | 2015 |
Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 8; Cisplatin; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Necrosis; Paclitaxel; Phosphorylation; Pregnancy; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Receptor-Interacting Protein Serine-Threonine Kinases; RNA Interference; Signal Transduction; Time Factors; Transfection; Treatment Outcome; Tyrosine; Xenograft Model Antitumor Assays | 2016 |
[A Patient with Lung Adenocarcinoma, Lymphangitis Carcinomatosa, and Multiple Bone Metastases Who Achieved Long-Term Survival after Successful Treatment with Carboplatin, Paclitaxel, and Bevacizumab].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Lymphangitis; Middle Aged; Paclitaxel; Time Factors | 2016 |
[A Patient with CA19-9-Producing Pulmonary Adenocarcinoma Who Responded to Multidisciplinary Therapy and Achieved Complete Response].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carboplatin; Chemotherapy, Adjuvant; Humans; Lung Neoplasms; Lymph Node Excision; Male; Neutropenia; Paclitaxel | 2016 |
[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Translocation, Genetic | 2017 |
Paclitaxel resistance development is associated with biphasic changes in reactive oxygen species, mitochondrial membrane potential and autophagy with elevated energy production capacity in lung cancer cells: A chronological study.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents, Phytogenic; Autophagy; Caspase 3; Cell Cycle; Drug Resistance, Neoplasm; Energy Metabolism; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Microscopy, Fluorescence; Paclitaxel; Reactive Oxygen Species | 2017 |
Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Peptide Mapping; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Taxol induces concentration-dependent apoptotic and paraptosis-like cell death in human lung adenocarcinoma (ASTC-a-1) cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Annexins; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Survival; Cytoplasm; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Microscopy, Confocal; Microscopy, Fluorescence; Paclitaxel; Vacuoles | 2010 |
Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-6; Janus Kinase 2; Lung Neoplasms; Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Tumor Cells, Cultured | 2010 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibiotics, Antineoplastic; Anticoagulants; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Chick Embryo; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Female; Heparin, Low-Molecular-Weight; Humans; Iodine Radioisotopes; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Tissue Distribution; Xenograft Model Antitumor Assays | 2011 |
Molecular selection trumps clinical selection.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Paclitaxel; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Proapoptotic lipid nanovesicles: synergism with paclitaxel in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Administration, Inhalation; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Synergism; Humans; Lung; Lung Neoplasms; Nanocapsules; Paclitaxel; Phosphatidylserines | 2011 |
[nm23-H1-siRNA enhances the chemosensitivity to liposome-encapsulated paclitaxel in lung adenocarcinoma cells in vitro].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; NM23 Nucleoside Diphosphate Kinases; Paclitaxel; RNA, Small Interfering; Transfection | 2011 |
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following carboplatin-paclitaxel administration in a patient with lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lung; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Vasopressins | 2011 |
Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adsorption; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Chemistry, Pharmaceutical; Doxorubicin; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Magnetite Nanoparticles; Paclitaxel; Porosity; Silicon Dioxide; Sirolimus | 2012 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Involvement of ROS in the inhibitory effect of thermotherapy combined with chemotherapy on A549 human lung adenocarcinoma cell growth through the Akt pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Enzyme Inhibitors; Humans; Hyperthermia, Induced; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Wortmannin; Xenograft Model Antitumor Assays | 2012 |
Effects of monoclonal antibodies against human stathmin combined with paclitaxel on proliferation of the QG-56 human lung carcinoma cell line.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Humans; Lung Neoplasms; Paclitaxel; Stathmin | 2012 |
Bronchoesophageal fistula and fatal hemoptysis after bevacizumab-containing chemotherapy without radiation in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bronchial Fistula; Bronchoscopy; Carboplatin; Esophageal Fistula; Fatal Outcome; Hemoptysis; Humans; Lung Neoplasms; Male; Paclitaxel; Stents; Tomography, X-Ray Computed; Tracheoesophageal Fistula | 2012 |
Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cost-Benefit Analysis; Decision Support Techniques; ErbB Receptors; Genetic Testing; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Precision Medicine; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; United States | 2012 |
Effect of trichostatin A and paclitaxel on the proliferation and apoptosis of lung adenocarcinoma cells.
Topics: Acetylation; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Paclitaxel; Tubulin | 2013 |